MS and Demyelinating Disorders

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Hartung, PharmD, MPH.

The antioxidants adiponectin, total radical-trapping antioxidant parameter, sulfhydryl groups, zinc, and soluble tumor necrosis factor receptor 2 all play a role in the pathophysiology of multiple sclerosis.

New retrospective data suggest that patients with MS who have comorbid conditions have increased all-cause hospital admission rates, especially early in the disease.

Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

Data from the MS SMART trial, which may serve as a template for simultaneous testing of multiple DMTs, suggest that exclusively targeting axonal pathobiology is inadequate to prevent neuroaxonal loss.

Neurology News Network for the week ending January 27, 2020.

As was the case for siponimod’s FDA approval in March 2019, this regulatory decision by the European Commission for the selective sphingosine-1-phosphate receptor modulator was based on the phase 3 EXPAND trial.

Neurology News Network for the week ending January 18, 2020.